Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
Investor's Business DailyIncyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment.
The post Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival appeared first on Investor's Business Daily.